Cryo Cell International Inc. CCEL
Misc Health and Biotechnology Services · IPO 2022 · data as of November 13, 2026
Cryo Cell International Inc. (CCEL) is a healthcare company listed in the US with a market value of about $39M. In the twelve months to August 31, 2026 it had revenue of $31M and net income of -$2M, a net margin of -6.2%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (1/5).
Key numbers: a price to free cash flow of 8.4, 5-year revenue growth of 0% a year, a 5-year average ROIC of 44%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 50% below the current price.
About Cryo Cell International
Cryo Cell International is listed in the US and classified in misc health and biotechnology services, IPO year 2022. Revenue went from $20M in 2014 to $32M in 2025, growth of about 4.2% a year. It was profitable in 6 of the last 10 years in our data. Its share count fell by 5% over three years (buybacks). It spends 1% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- 5-year average ROIC above 12%
- Positive free cash flow
- Debt below 3 years of free cash flow
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31M | $32M | $32M | $31M | $30M | $29M | $31M | $32M | $29M | $25M | $23M |
| Net income | -$2M | -$2M | $402095 | -$10M | $3M | $2M | $4M | $2M | -$854824 | $2M | -$1M |
| Free cash flow | $5M | $5M | $4M | $2M | -$4M | $6M | $8M | $6M | $5M | $6M | $5M |
| EPS (diluted) | $-0.23 | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.25 | $0.45 | $0.27 | $-0.11 | $0.30 | $-0.16 |
| Net margin | -6.2% | -7.7% | 1.3% | -30.4% | 9.1% | 7.2% | 11.6% | 7.2% | -2.9% | 9.1% | -5.7% |
| ROIC | — | — | — | — | 43.0% | 45.8% | 154.1% | 170.7% | 101.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Cryo Cell International stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 50% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cryo Cell International pay a dividend?
Not currently.
Is Cryo Cell International a good stock to buy?
We do not give buy or sell advice. Cryo Cell International scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.